Identification of clinical biomarkers for adjuvant chemotherapy in gastric cancer after D2 dissection by pooled analysis of individual patient data from three large randomized clinical trials

Shiro Tanaka; Jia Guan; Kazuhiro Yoshida; Michiya Kobayashi; Shigefumi Yoshino; Kazuaki Tanabe; Takaki Yoshikawa; Takashi Oshima; Yumi Miyashita; Junichi Sakamoto; Akira Tsuburaya

doi:10.4993/acrt.26.43

Shiro Tanaka, Jia Guan, Kazuhiro Yoshida, Michiya Kobayashi, Shigefumi Yoshino, Kazuaki Tanabe, Takaki Yoshikawa, Takashi Oshima, Yumi Miyashita, Junichi Sakamoto, Akira Tsuburaya

Author information

Keywords: Gastric cancer, Adjuvant chemotherapy, Clinical biomarker, Meta-analysis

JOURNAL FREE ACCESS

2018 Volume 26 Issue 1 Pages 43-45

DOI https://doi.org/10.4993/acrt.26.43

Details

Abstract

We aimed to identify prognostic and predictive markers among clinicopathological factors for efficacy of adjuvant chemotherapy in gastric cancer by pooled analysis from 3,521 patients on three large randomized trials: ACTS-GC, CLASSIC, and SAMIT. The primary endpoint was relapse-free survival, and the secondary endpoints were overall survival. The integrity of individual patient data was verified. Significant prognostic markers in surgery alone groups of ACTS-GC and CLASSIC were lower body mass index and advanced stage of disease.

Corresponding author

Register with J-STAGE for free!